Monthly Archives: May 2016

CRISPR/Cas genome editing has captured the attention of the popular media, scientific community, and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certainly captivating.

Jumping into a first-time CEO role in an emerging biotech is a daunting but exciting opportunity – both for the newly-minted chief executive and their Board of Directors. A great hire can be positively catalytic to a startup; and, sadly,

This blog was written by Vanessa King, CEO of Luc Therapeutics, as part of the From The Trenches feature of LifeSciVC Almost 15 years ago – in 2003, to be precise – I was working with genome sequencing pioneer Craig

Startup ecosystems supported by venture capital are defined by dynamism, with the creation, growth, exiting, or failure of new innovative companies conspiring to keep these entrepreneurial landscapes in constant change. Investor returns and sentiment are dramatically impacted by how these

This post was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. Ex-Citigroup CEO Charles Prince famously said in July 2007, regarding Citi’s leveraged lending business, “As long as the music